{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Renal+Cell+Carcinoma&page=2", "query": { "condition": "Advanced Renal Cell Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Renal+Cell+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-07T16:42:26.593Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00091611", "title": "Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kidney Neoplasms" ], "interventions": [ { "name": "IL-2 (interleukin-2)", "type": "DRUG" }, { "name": "OKT3", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2004-09", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2012-10-26", "last_synced_at": "2026-06-07T16:42:26.593Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00091611" }, { "nct_id": "NCT06682793", "title": "A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Colorectal Cancer", "Non-Small Cell Lung", "NSCLC (Non-small Cell Lung Cancer)", "Cancer", "Colon Cancer", "Rectal Cancer", "Lung Cancer", "CRC", "Head and Neck Squamous Cell Cancer", "HNSCC", "Renal Cell Carcinoma", "RCC", "Kidney Cancer", "Triple Negative Breast Cancer", "TNBC", "Colorectal Adenocarcinoma" ], "interventions": [ { "name": "A2B395", "type": "BIOLOGICAL" }, { "name": "xT CDx with HLA-LOH assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST" ], "sponsor": "A2 Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2025-05-22", "completion_date": "2030-03-31", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-06-07T16:42:26.593Z", "location_count": 10, "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06682793" }, { "nct_id": "NCT01277744", "title": "Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Cancers", "Sarcoma" ], "interventions": [ { "name": "Hyperthermic Peritoneal Perfusion (HIPEC)", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 22, "start_date": "2011-05-09", "completion_date": "2018-02-16", "has_results": true, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-06-07T16:42:26.593Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01277744" }, { "nct_id": "NCT03961698", "title": "Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "IPI-549 (eganelisib)", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Infinity Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2019-12-17", "completion_date": "2023-08-31", "has_results": false, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-06-07T16:42:26.593Z", "location_count": 24, "location_summary": "Chandler, Arizona • Tucson, Arizona • Fullerton, California + 20 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03961698" }, { "nct_id": "NCT06053658", "title": "Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Tivozanib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2024-01-05", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-06-07T16:42:26.593Z", "location_count": 6, "location_summary": "Irvine, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06053658" }, { "nct_id": "NCT02009449", "title": "A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Prostate Cancer", "Ovarian Cancer", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Pancreatic Carcinoma", "Non-small Cell Lung Carcinoma", "Solid Tumors", "Breast Cancer" ], "interventions": [ { "name": "Pegilodecakin", "type": "DRUG" }, { "name": "Paclitaxel or Docetaxel and Carboplatin or Cisplatin", "type": "DRUG" }, { "name": "FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)", "type": "DRUG" }, { "name": "gemcitabine/nab-paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "Gemcitabine/carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 353, "start_date": "2013-11-15", "completion_date": "2023-07-22", "has_results": false, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-06-07T16:42:26.593Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02009449" }, { "nct_id": "NCT00006968", "title": "Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "pentostatin", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2000-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-08", "last_synced_at": "2026-06-07T16:42:26.593Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006968" }, { "nct_id": "NCT02771626", "title": "Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma (ccRCC)", "Melanoma", "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "CB-839", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2016-08-01", "completion_date": "2020-04-24", "has_results": true, "last_update_posted_date": "2023-03-17", "last_synced_at": "2026-06-07T16:42:26.593Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Athens", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02771626" }, { "nct_id": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Solid Tumors", "NSCLC", "Bladder Cancer", "HNSCC", "Renal Cancer", "Melanoma", "Anal Cancer", "Colorectal Cancer", "Cholangiocarcinoma", "Gastric Cancer", "Hepatocellular Carcinoma", "Merkel Cell Carcinoma", "Cervical Cancer" ], "interventions": [ { "name": "Continue PD-1/PD-L1 Inhibitors treatment", "type": "DRUG" }, { "name": "Discontinue PD-1/PD-L1-1 inhibitor", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Dan Zandberg", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2019-11-15", "completion_date": "2025-11-07", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-06-07T16:42:26.593Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04157985" }, { "nct_id": "NCT02837991", "title": "A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma (RCC)", "Clear-cell Renal Cell Carcinoma", "Papillary Renal Cell Carcinoma", "Kidney Neoplasms", "Metastatic Renal Cell Carcinoma", "Ovarian Clear Cell Carcinoma" ], "interventions": [ { "name": "CDX-014", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2016-06", "completion_date": "2018-11-16", "has_results": false, "last_update_posted_date": "2020-06-04", "last_synced_at": "2026-06-07T16:42:26.593Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Boston, Massachusetts + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02837991" } ] }